BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12802932)

  • 1. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
    Davis TS
    Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
    Todeschini G; Gelio S; Tecchio C
    Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
    Bernardi D; Giacalone A; Spina M; Tirelli U
    Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
    Mikuls TR
    Ann Oncol; 2007 Apr; 18(4):615-8. PubMed ID: 17355949
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
    Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
    Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI
    Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
    Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
    Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
    [No Abstract]   [Full Text] [Related]  

  • 11. Echocardiographic findings of intracardiac mass.
    Tanaka H; Kawai H; Ishida T; Yoshida A; Yokoyama M
    J Cardiol; 2007 Aug; 50(2):155-7. PubMed ID: 17802700
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma.
    Shimada K; Kosugi H; Narimatsu H; Shimada S; Suzuki T; Ito M; Kinoshita T; Mori N; Naoe T
    J Clin Exp Hematop; 2008 Apr; 48(1):25-8. PubMed ID: 18434690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubulointerstitial capillaries limited intravascular lymphoma of the kidney.
    Kimura Y; Takeuchi M; Matsue K
    Int J Hematol; 2017 Nov; 106(5):589-590. PubMed ID: 28755205
    [No Abstract]   [Full Text] [Related]  

  • 14. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular lymphomatosis presenting as an ascending cauda equina: conus medullaris syndrome: remission after biweekly CHOP therapy.
    Nakahara T; Saito T; Muroi A; Sugiura Y; Ogata M; Sugiyama Y; Yamamoto T
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):403-6. PubMed ID: 10449569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary hepatic lymphoma - favorable outcome with chemotherapy plus rituximab].
    Serrano-Navarro I; Rodríguez-López JF; Navas-Espejo R; Pérez-Jacoiste MA; Martínez-González MA; Grande C; Prieto S
    Rev Esp Enferm Dig; 2008 Nov; 100(11):724-8. PubMed ID: 19159179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in the treatment of diffuse large B-cell lymphomas.
    Coiffier B
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):30-5. PubMed ID: 11842386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.
    Rey J; Charbonnier A; Schiano de Colella JM; Stoppa AM; Poizot-Martin I; Gastaut JA; Costello RT
    AIDS; 2003 Sep; 17(13):2006-7. PubMed ID: 12960844
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary effusion lymphoma (PEL) revisited: a hematologist's perspective.
    Desai S; Freeman NJ
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):60-1. PubMed ID: 16163162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.